Versant Venture Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Versant Venture Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-410,360	Closed	-$9.01M	–	10
2022 Q1	$9.01M	Hold	410,360	–	–	8.99%	4
2021 Q4	$11.7M	Sell	410,360 -410,360	-50%	-$10.1M	6.24%	6
2021 Q3	$17.3M	Hold	820,720	–	–	7.15%	5
2021 Q2	$15.5M	Sell	820,720 -1,209,896	-60%	-$21.3M	5.13%	6
2021 Q1	$31M	Hold	2,030,616	–	–	6.05%	6
2020 Q4	$28.7M	Hold	2,030,616	–	–	2.98%	7
2020 Q3	$31.8M	Hold	2,030,616	–	–	5.82%	5
2020 Q2	$35.6M	Buy	+2,030,616	New	+$34.6M	5.11%	5

Other funds holding CRNX

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Versant Venture Management's CRNX Position: Q2 2022 in Review

Versant Venture Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2022, closing a stake of 410,360 shares — an estimated $9.01M sold.

Versant Venture Management first reported a position in CRNX in Q2 2020 and held it in 8 quarters. The position peaked at $35.6M in Q2 2020. 111 funds tracked by Wall St. Rank hold CRNX as of Q2 2022.

Versant Venture Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Versant Venture Management sold 410,360 Crinetics Pharmaceuticals shares in Q2 2022, an estimated $9.01M.
Versant Venture Management first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Versant Venture Management's Crinetics Pharmaceuticals position peaked at $35.6M in Q2 2020.
111 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2022.

Based on Versant Venture Management's 13F filing for Q2 2022, filed 11 Aug 2022.